Nivolumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Nivolumab (coding:ncit:C68814)

RxNorm: nivolumab (coding:rxcui:1597876, coding:omop:45892628)

SNOMED: Nivolumab (coding:sctid:704191007, coding:omop:45766924)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
FDA (2) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) HC (2) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (1) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
FDA (2) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) MSI-H Colorectal Adenocarcinoma Nivolumab
FDA (1) dMMR Colorectal Adenocarcinoma Nivolumab
HC (2) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Ipilimumab, Nivolumab
HC (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
HC (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Nivolumab, Oxaliplatin
HC (1) BRAF p.V600E Melanoma Nivolumab
HC (1) BRAF p.V600K Melanoma Nivolumab